The latest focusIR Investor Webinar with speakers from: Pyx Resources, Helix Exploration, Fulcrum Metals and Metals One takes place on Tuesday 23rd July. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12.80
Bid: 12.60
Ask: 13.00
Change: -0.30 (-2.33%)
Spread: 0.40 (3.175%)
Open: 12.90
High: 12.60
Low: 12.60
Prev. Close: 12.90
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down

Tue, 30th Apr 2024 16:30

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:


Cizzle Biotechnology Holdings PLC - London diagnostics developer company engaged in developing a blood test for the early detection of the different forms of lung cancer - Reports operating loss before tax in 2023 widens to GBP1.8 million from GBP963,000 a year prior. This reflects increase in administrative expenses to GBP1.8 million from GBP963,000. Loss per basic and diluted share is 0.5 pence compared to 0.3p. No revenue declared, unchanged. Intends that the group's initial commercial product will be based on a platform that can be readily performed by hospitals and reference laboratories. Envisages that potential follow-on products could be immunoassay kits and a point of

care test provided by primary health care providers. Feels well placed to meet key milestones planned for the launch of its first commercial product. Continues discussions with existing partners in the US and China to develop its future opportunities in global markets.


Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Says revenue in 2023 more than doubles to GBP23.2 million from GBP9.7 million. Cost of sales multiplies to GBP12.0 million from GBP2.4 million. Pretax loss narrows to GBP27.3 million from GBP41.6 million. Chair Eliot Forster comments: "The clinical momentum demonstrated by AVA6000 during the reporting period and into the post-period has significantly enhanced our confidence in AVA6000 and the broader pre/CISION platform."


Poolbeg Pharma PLC - London-based clinical-stage biopharmaceutical company - In 2023, says pretax loss narrows to GBP4.5 million from GBP4.8 million a year prior. Nil revenue, unchanged. Administrative expenses tick up to GBP3.4 million from GBP3.1 million but research and development costs fall to GBP1.7 million from GBP2.2 million. Loss per share totals 0.79 pence compared to 0.94p before. Further, enters exclusive 12-month option agreement with Silk Road Therapeutics Inc, for a nominal fee, to acquire a muco-adherent formulation of Pentoxifylline for the treatment of oral ulcers in patient's suffering from Behcet's disease. Notes a Phase 2 trial has successfully completed, demonstrating superiority over standard of care. Plans to continue due diligence throughout the term of the agreement which will include engagement with Silk Road Therapeutics to ascertain the clinical approval pathway.


Digital 9 Infrastructure PLC - investor in internet infrastructure, such as data centres and subsea fibre - In 2023, reports net asset value falls to 79.33 pence from 109.76p a year prior. Halves dividend to 3p per share from 6p. Loss per share is 27.43p compared to EPS of 11.09p. Debt increases to GBP544.8 million from GBP494.2 million. Explains NAV decline was primarily due to a GBP179.3 million change in the fair value of the investment portfolio. The latter included GBP32.8 million of foreign exchange movements, which primarily related to Verne Global. Also reflects increased costs, such as interest expenses and professional fees. In March, Digital 9 completed the sale of its entire stake in the Verne Global group of companies to funds managed or advised by Ardian France SA for up to USD575 million, around GBP450 million.


RBG Holdings PLC - London-based legal and professional services firm - In 2023, says revenue falls 13% to GBP39.2 million from GBP44.9 million a year prior, while pretax loss widens to GBP11.4 million from GBP2.1 million. Basic loss per share from continuing operations is 11.58 pence compared to 1.73p. Calls 2023 a "very challenging year." Says trading in the first quarter of 2024 has been in line with expectations. Expresses optimism that 2023 marked the end of the pivot from the group's previous strategy and that there are opportunities for the group to grow.


Smarttech247 Group PLC - Cork, Ireland-based artificial intelligence-enhanced cybersecurity services provider - In the six months to January, reports revenue of EUR5.4 million, up 17% from EUR4.6 million a year prior. Operating expenses rise 58% to EUR4.1 million from EUR2.6 million. Pretax loss widens to EUR601,000 from EUR450,000. Basic and diluted earnings per share are EUR0.53 compared to EUR0.86.

Chief Executive Raluca Saceanu comments: "As the cybersecurity landscape continues to evolve and we see new threats daily, we are signing new contracts, expanding our business pipeline and adapting our product offerings and technology to ensure we can meet our clients' vital cybersecurity needs." Adds: "Positive about the prospects for the second half of FY2024 and for the year as a whole."


Kelso Group Holdings PLC - investor in 'undervalued' London-listed companies - Swings to pretax profit of GBP2.0 million in 2023 from loss of GBP289,324 a year prior. Revenue totals GBP2.6 million compared to zero. Administrative expenses rise to GBP460,430 from GBP287,857. Earnings per diluted share are 0.56 pence compared to LPS of 0.61p. Chief Executive John Goold says: "We are pleased to deliver Kelso's first set of financial results, highlighting the successful implementation of its strategy to assist UK listed companies unlock their true value. Kelso's Board is committed to the success of the company and continues to actively review new investment opportunities." "The UK stock market remains challenging but we hope initiatives like the new British ISA will help stimulate demand, in particular for the UK's smaller companies which remain lowly valued," company says.


Northcoders Group PLC - Manchester-based software coding training provider - In 2023, reports revenue rises 27% to a record GBP7.1 million from GBP5.6 million a year prior driven by geographic expansion and entry into new disciplines. Despite this, swings to pretax loss of GBP1.2 million from GBP346,429 profit. Cost of sales increases to GBP2.7 million from GBP1.7 million, while amortisation and impairment charges near treble to GBP234,225 from GBP85,167. Adjusted loss per share is 4.81 pence compared to EPS of 8.02p. Reports record growth in numbers of individuals trained, increasing to 2,852 from 1,685 the year before. Says both business-to-customer and business-to-business divisions start 2024 strongly, with record B2C applications and a growing pipeline for B2B contracts. Notes revenue access and contracted visibility already reaches GBP8.3 million for 2024. Overall, 2024 trading is in line with expectations.


By Jeremy Cutler, Alliance News reporter

Comments and questions to

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
6 Jun 2024 14:52

UK shareholder meetings calendar - next 7 days

Friday 7 June 
Property Franchise Group PLCAGM
Trident Royalties PLCAGM
TruSpine Technologies PLCAGM
Monday 10 June 
Aterian PLCAGM
Griffin Mining LtdAGM
Lok'n Store Group PLCGM re takeover by Shurgard
Onward Opportunities LtdAGM
Oxford Nanopore Technologies PLCAGM
Pan African Resources PLCGM re capital reduction
Tuesday 11 June 
Ebiquity PLCAGM
Flowtech Fluidpower PLCAGM
MaxCyte IncAGM
Mobico Group PLCAGM
Newbury Racecourse PLCAGM
Nightcap PLCGM re fundraise
Phoenix Digital Assets PLCGM re up to GBP33.7 million fundraise
Tirupati Graphite PLCGM requisitioned by Walpole St Andrews Nominees
Tortilla Mexican Grill PLCAGM
Tufton Oceanic Assets LtdEGM
Wednesday 12 June 
Advanced Medical Solutions Group PLCAGM
Alina Holdings PLCAGM
Aquila Energy Efficiency Trust PLCAGM
Aurora Investment Trust PLCAGM
BioPharma Credit PLCAGM
Brighton Pier Group PLCAGM
Digital 9 Infrastructure PLCAGM
EPE Special Opportunities LtdAGM
Foresight Solar Fund LtdAGM
Star Energy Group PLCAGM
Thursday 13 June 
Beacon Rise Holdings PLCAGM
Christie Group PLCAGM
Everyman Media Group PLCAGM
Hochschild Mining PLCAGM
Jadestone Energy PLCAGM
Panther Metals PLCAGM
Pollen Street Group LtdAGM
Poolbeg Pharma PLCAGM
Serabi Gold PLCAGM
Smurfit Kappa Group PLCGM re WestRock deal
Sound Energy PLCAGM
Starwood European Real Estate Finance LtdAGM
Comments and questions to
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
1 May 2024 16:39

Poolbeg Pharma celebrates full patent approval for Immunomodulator II

(Alliance News) - Poolbeg Pharma PLC on Wednesday said that it has received a fully granted patent from the US Patent Office for its Immunomodulator II patent application.

Read more
30 Apr 2024 16:43

Poolbeg agrees 12-month option over potential Behcet's treatment

(Sharecast News) - Poolbeg Pharma announced an exclusive 12-month option agreement with Silk Road Therapeutics on Tuesday, to potentially acquire a novel topical muco-adherent formulation of Pentoxifylline (tPTX).

Read more
20 Mar 2024 16:18

EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Mar 2024 11:10

Poolbeg Pharma to be granted US patent

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has received a notice of allowance from the US Patent Office regarding its immunomodulator II patent application.

Read more
19 Feb 2024 14:22

Director dealings: Poolbeg Pharma co-founder ups stake

(Sharecast News) - Poolbeg Pharma revealed on Monday that chairman Cathal Friel had acquired 830,000 ordinary shares in the AIM-listed biopharmaceutical company.

Read more
15 Feb 2024 16:02

TRADING UPDATES: Diversified Energy offers dividend alternative

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
12 Feb 2024 19:44

TRADING UPDATES: Katoro Gold launches fundraising, eyes board shake-up

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
12 Feb 2024 14:37

Poolbeg upbeat on research into potential drug market

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced findings from independent research confirming a substantial market opportunity exceeding $10bn for its drug candidate POLB 001 on Monday, in preventing cancer immunotherapy-induced cytokine release syndrome (CRS) through oral delivery.

Read more
17 Jan 2024 13:58

Poolbeg Pharma hails POLB 001'S potential to treat CRS

(Alliance News) - Poolbeg Pharma PLC on Wednesday noted "promising" results for POLB 001's potential in treating cancer immunotherapy-induced cytokine release syndrome.

Read more
20 Dec 2023 20:00

TRADING UPDATES: K3 Business says cash balances ahead of forecast

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Dec 2023 13:54

Poolbeg makes promising progress with RSV programme

(Sharecast News) - Poolbeg Pharma revealed promising results from the lab-based analysis and prioritisation of respiratory syncytial virus (RSV) drug targets and treatments on Wednesday, driven by its artificial intelligence (AI) programme.

Read more
21 Nov 2023 14:39

TRADING UPDATES: Poolbeg hails approval; EDX links with Thermo Fisher

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
9 Nov 2023 16:57

IN BRIEF: Poolbeg Pharma appoints former Amryt executives to team

Poolbeg Pharma PLC - Clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need - Appoints a number of former executives of Amryt Pharma PLC to its leadership team. Poolbeg's Chair, Cathal Friel, co-founded both Poolbeg and Amryt Pharma.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.